Entrada Therapeutics Inc (TRDA) — Cash Flow Reinvestment Rate
Entrada Therapeutics Inc (TRDA) has a Cash Flow Reinvestment Rate of 0.64x as of June 2024, reinvesting $25.43 Million (capex $1.05 Million plus investments $-24.38 Million) from operating cash flow of $39.83 Million. See TRDA cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Entrada Therapeutics Inc Cash Flow Reinvestment Rate (2023–2023)
Historical reinvestment intensity for Entrada Therapeutics Inc across 1 annual periods. For the full cash flow conversion analysis, see how efficiently does Entrada Therapeutics Inc generate cash.
Annual Cash Flow Reinvestment Rate for Entrada Therapeutics Inc (2023–2023)
Year-by-year capital reinvestment analysis for Entrada Therapeutics Inc. See financial agility of Entrada Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 1.03x | $144.26 Million | $139.80 Million | $5.61 Million | — |